0.4201

2.25% -0.0198

Altamira Therapeutics Ltd (CYTO)

Overview News Price History Why CYTO Down? Discussions Forecast Stock Split

Altamira Therapeutics Ltd stock is traded at $0.4201, with a volume of 3,684. It is down -2.25% in the last 24 hours and down -25.23% over the past month. Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows to deliver of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.

Previous Close:

$0.4399

Open:

$0.424

24h Volume:

3,684

Relative Volume:

0.05

Market Cap:

$1.61M

Revenue:

$132.70K

Net Income/Loss:

$-25.04M

P/E Ratio:

-0.0203

EPS:

-20.6616

Net Cash Flow:

1W Performance:

+0.00%

1M Performance:

-25.23%

6M Performance:

-70.95%

1Y Performance:

-94.16%

1-Day Range:

$0.4058

$0.43

1-Week Range:

$0.40

$0.4998

52-Week Range:

$0.40

$17.20

Altamira Therapeutics Ltd Stock (CYTO) Company Profile

Name

Altamira Therapeutics Ltd

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

Address

Employee

Twitter

Next Earnings Date

2024-09-24

Latest SEC Filings

CYTO's Discussions on Twitter

Compare CYTO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CYTO	0.43	1.61M	132.70K	-25.04M	0	-20.66
VRTX	447.03	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.05	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	587.61	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.22	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.84	24.49B	3.30B	-501.07M	1.03B	11.54

Altamira Therapeutics Ltd Stock (CYTO) Latest News

Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Altamira Therapeuti - GuruFocus.com

Nov 14, 2024

Oct 22, 2024

CYTO stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com Australia

Oct 22, 2024

Oct 15, 2024

Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now - Nasdaq

Oct 15, 2024

Oct 11, 2024

Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets - AsiaOne

Oct 11, 2024

Oct 05, 2024

Altamira Therapeutics faces Nasdaq delisting over share price - Investing.com India

Oct 05, 2024

Altamira Therapeutics Provides Update on Nasdaq Listing - The Manila Times

Oct 05, 2024

Oct 04, 2024

Altamira Therapeutics Faces Nasdaq Delisting - TipRanks

Oct 04, 2024

Altamira Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK

Oct 04, 2024

Sep 30, 2024

CYTO stock plunges to 52-week low, touches $0.65 By Investing.com - Investing.com South Africa

Sep 30, 2024

CYTO stock plunges to 52-week low, touches $0.65 - Investing.com India

Sep 30, 2024

Sep 28, 2024

Altamira Medica obtains extended ISO 13485 certification By Investing.com - Investing.com South Africa

Sep 28, 2024

Sep 27, 2024

Altamira Medica obtains extended ISO 13485 certification - Investing.com

Sep 27, 2024

Altamira Therapeutics Announces Extended ISO 13485 Quality - GlobeNewswire

Sep 27, 2024

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray - StockTitan

Sep 27, 2024

Sep 25, 2024

Earnings call: Altamira Therapeutics focuses on RNA delivery growth By Investing.com - Investing.com Australia

Sep 25, 2024

Earnings call: Altamira Therapeutics focuses on RNA delivery growth - Investing.com

Sep 25, 2024

Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2024 Earnings Call Transcript - Insider Monkey

Sep 25, 2024